Gold prices bounce off 3-week lows; demand likely longer term
LONDON - PureTech Health plc (Nasdaq:PRTC, LSE: PRTC) announced Wednesday that Bharatt Chowrira has stepped down from his position as Chief Executive Officer and board member, with Robert Lyne appointed as Interim CEO, effective immediately.
Lyne, who joined PureTech in January 2024 as Chief Portfolio Officer, previously served as CEO of Arix Bioscience plc. According to the company’s press release statement, he will work with PureTech’s board and management team to advance the company’s strategic objectives.
Sharon Barber-Lui, Interim Chair of PureTech’s Board of Directors, thanked Chowrira for his eight years of service to the company, noting the board remains "focused on driving shareholder value."
Chowrira expressed pride in the company’s accomplishments during his tenure, including the advancement of clinical programs. "I leave with full confidence in the strength of the team and the exciting opportunities ahead for PureTech," he stated.
Lyne described his appointment as "an honor" and highlighted PureTech’s "high-value portfolio," stating he looks forward to advancing programs and delivering "meaningful milestones to create value for patients and shareholders."
PureTech Health is a clinical-stage biotherapeutics company focused on developing treatments for various diseases. The company has developed 29 therapeutics and therapeutic candidates, including three that have received FDA approval.
The leadership change comes as the company continues to advance its pipeline of therapeutic candidates across various indications and stages of clinical development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.